Resverlogix Corp (RVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Resverlogix Corp (RVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH82146D
  • |
  • Pages: 35
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Resverlogix Corp (Resverlogix) is a biotechnology company that develops small molecule therapeutics for cardiovascular disease, diabetes mellitus, and chronic kidney disease. The company's lead product candidate include Apabetalone (RVX-208) is a first-in-class small molecule that inhibits BET bromodomain proteins for the treatment of high-risk cardiovascular disease patients with type 2 diabetes mellitus and low high-density lipoprotein (HDL), and Alzheimer's disease. Resverlogix utilizes an epigenetics drug development platform, BET technology, to target BET proteins and identify small molecule candidates that specifically bind to BET bromodomains and regulate gene expression, among others. It also discovers and develops therapeutics for neurodegenerative diseases, peripheral artery disease and rare orphan diseases. The company operates through its representative office located in San Francisco, California, the US. Resverlogix is headquartered in Calgary, Alberta, Canada.

Resverlogix Corp (RVX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Resverlogix Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Resverlogix Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Resverlogix Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Resverlogix Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Resverlogix Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Resverlogix Corp, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Resverlogix Enters into Research Agreement with Emerald Logic 10

Licensing Agreements 11

Medison Pharma Enters into Licensing Agreement with Resverlogix 11

Hepalink USA to Enter into Licensing Agreement with Resverlogix 12

Resverlogix Enters into Licensing Agreement with Shenzhen Hepalink Pharma 13

Equity Offering 14

Resverlogix Raises USD20 Million in Private Placement of Units 14

Resverlogix Withdraws Private Placement of Units 15

Resverlogix Raises USD69.8 Million in Private Placement of Units 16

Resverlogix to Raise USD3.6 Million in Private Placement of Units 17

Resverlogix Raises USD3.4 Million in Public Offering of Units 18

Resverlogix Raises USD4 Million in Private Placement of Units 19

Resverlogix Raises USD0.2 Million in Private Placement of Shares 21

Resverlogix Raises USD41.4 Million in Private Placement of Units 22

Resverlogix Raises USD2 Million in Private Placement of Shares 23

Resverlogix Completes Private Placement Of Units For USD 1.5 Million 24

Resverlogix Completes Spin-Off of Zenith Epigenetics 25

Resverlogix Completes First Tranche Of Private Placement Of Shares For USD 0.2 Million 26

Resverlogix Corp-Key Competitors 27

Resverlogix Corp-Key Employees 28

Resverlogix Corp-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Corporate Communications 30

Jul 31, 2018: Resverlogix intends to Pursue U.S. Listing 30

May 10, 2018: Resverlogix Announces Lifting by TSX of Review 31

Apr 12, 2018: Resverlogix Announces TSX Review Update 32

Other Significant Developments 33

Feb 08, 2018: Resverlogix Highlights Key Accomplishments and 2018 Targets 33

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35

List of Figures

Resverlogix Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Resverlogix Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Resverlogix Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Resverlogix Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Resverlogix Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Resverlogix Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Resverlogix Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Resverlogix Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

List of Tables

Resverlogix Corp, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Resverlogix Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Resverlogix Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Resverlogix Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Resverlogix Corp, Deals By Therapy Area, 2012 to YTD 2018 8

Resverlogix Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Resverlogix Enters into Research Agreement with Emerald Logic 10

Medison Pharma Enters into Licensing Agreement with Resverlogix 11

Hepalink USA to Enter into Licensing Agreement with Resverlogix 12

Resverlogix Enters into Licensing Agreement with Shenzhen Hepalink Pharma 13

Resverlogix Raises USD20 Million in Private Placement of Units 14

Resverlogix Withdraws Private Placement of Units 15

Resverlogix Raises USD69.8 Million in Private Placement of Units 16

Resverlogix to Raise USD3.6 Million in Private Placement of Units 17

Resverlogix Raises USD3.4 Million in Public Offering of Units 18

Resverlogix Raises USD4 Million in Private Placement of Units 19

Resverlogix Raises USD0.2 Million in Private Placement of Shares 21

Resverlogix Raises USD41.4 Million in Private Placement of Units 22

Resverlogix Raises USD2 Million in Private Placement of Shares 23

Resverlogix Completes Private Placement Of Units For USD 1.5 Million 24

Resverlogix Completes Spin-Off of Zenith Epigenetics 25

Resverlogix Completes First Tranche Of Private Placement Of Shares For USD 0.2 Million 26

Resverlogix Corp, Key Competitors 27

Resverlogix Corp, Key Employees 28

Resverlogix Corp, Other Locations 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Resverlogix Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17848
Site License
USD 500 INR 35695
Corporate User License
USD 750 INR 53543

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com